Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||INCB054329 + INCB059872|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|INCB054329||INCB-054329||BET Inhibitor (Pan) 27||INCB054329 is BET inhibitor, which results in decreased expression of BET protein-regulated genes including MYC, potentially leading to decreased tumor cell proliferation (PMID: 30206163)|
|INCB059872||KDM1A Inhibitor 12||INCB059872 is a specific inhibitor of lysine specific demethylase 1 (KDM1A, LSD1) that increases tumor-suppressor gene expression through enhancing Histone H3 methylation, leading to anti-tumor effects (Cancer Res 2016;76(14 Suppl):Abstract nr 4704).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||acute myeloid leukemia||not applicable||INCB054329 + INCB059872||Preclinical - Cell line xenograft||Actionable||In a preclinical study, combination of INCB054329 and INCB059872 resulted in enhanced apoptosis in acute myeloid leukemia cells in culture and in cell-line xenograft models (Cancer Res 2016;76(14 Suppl):Abstract nr 4702).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|